Neurocrine Biosciences | NBIX - 市值



金融业
股票价格
USD
资产
USD 5.36B
现金及等价物
USD 332.4M
销售成本
USD 39.4M
流动资产
USD 1.64B
流动负债
USD 874.5M
债务
USD 406.2M
EBIT
USD 219.9M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 2.85
股本和储备
USD 3.69B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.23B
净收入
USD 144.4M
营业费用
USD 739.1M
营业利润
USD 219.9M
普通股股本
USD 100.55M
PE价格收益
22.1
税前利润
USD 246.8M
销售收入
USD 959M
销售和管理费用
USD 383.1M
股票
USD 104.2M
贸易债权人
USD 691.3M
应收帐款人
USD 887M


市值 更改 日
AbbVie USD 435.86B 8.73B 2026-08
Acadia Pharmaceuticals USD 4.53B 199M 2026-08
ALKERMES USD 7.93B 806M 2026-08
Alnylam Pharmaceuticals USD 40.19B 3.96B 2026-06
Amgen USD 209.65B 14.21B 2026-08
Biogen USD 31.9B 5B 2026-06
BioMarin Pharmaceutical USD 11.71B 651M 2026-08
Cytokinetics USD 9.6B 1.95B 2026-08
Enanta Pharmaceuticals USD 122M 98M 2024-12
Exelixis USD 15.27B 1.73B 2026-08
Gilead Sciences USD 168.68B 11.82B 2026-08
Halozyme Therapeutics USD 10.91B 1.63B 2026-08
Incyte USD 26.84B 4.19B 2026-08
Ionis Pharmaceuticals USD 13.1B 642M 2026-06
Nektar Therapeutics USD 12.98B 10.86B 2026-08
Neurocrine Biosciences USD 16.95B 3.7B 2026-06
Pfizer USD 153.17B 14.73B 2026-08
Prothena USD 516M 2M 2026-03
Regeneron Pharmaceuticals USD 65.37B 16.31B 2026-06
Repligen USD 7.86B 168M 2026-08
Sarepta Therapeutics USD 1.5B 402M 2026-08
Teva Pharmaceutical Industries USD 114.54B 80.27B 2026-06
Ultragenyx Pharmaceutical USD 2.12B 1.16B 2026-08
Vertex Pharmaceuticals USD 137.33B 11.26B 2026-08